Benzinga | Nov 19, 2021 08:32AM EST

Arena Pharma Reports Achieved Target Enrollment For Etrasimod CULTIVATE Study A

- Evaluating 2 mg and 3 mg etrasimod in study participants with moderate to severe Crohn's Disease (CD)

- Topline data from CULTIVATE Study A on track for Q2 2022

PARK CITY, Utah--(BUSINESS WIRE)-- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that it has achieved target enrollment in Study A of the Phase 2/3 CULTIVATE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate to severe Crohn's disease (CD). CULTIVATE Study A reached target enrollment of 70 study participants to assess etrasimod 2 mg and 3 mg in participants with CD.

"Crohn's disease patients have an intense need for additional therapeutic options, particularly for a safe and effective oral option," said Doug Manion, MD, FRCP (C) Executive Vice President, Research & Development at Arena. "We are already progressing etrasimod into the next study in the CULTIVATE program and look forward to seeing the topline data from Study A in Q2 2022."